{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-004324","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2025-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.570626+00:00","generated_at":"2026-05-18T09:24:02.438090+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioCryst appoints Babar Ghias as CFO and Head of Corporate Development","bullets":["Babar Ghias named CFO, effective July 7, 2025; also serves as Principal Accounting Officer.","Annual base salary of $560,000; target bonus 70% of salary; one-time cash bonus of $160,000.","Inducement grants: 147,000 RSUs and options to purchase 305,000 shares, vesting over 4 years.","Ghias joins from AvenCell Therapeutics; previously EVP at Paragon Biosciences and CFO at Marathon Pharmaceuticals.","CEO Stonehouse cites Ghias' deal-making and operational experience for growth and capital deployment."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-004324","json":"https://secwatch.observer/filing/0001171843-25-004324.json","markdown":"https://secwatch.observer/filing/0001171843-25-004324.md","text":"https://secwatch.observer/filing/0001171843-25-004324.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184325004324/0001171843-25-004324-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184325004324/f8k_070725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:24:02.438090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}